Released on Friday, February 7, the January jobs report showed resilience in the labor market with higher-than-expected wage ...

“It would have been possible [to do the project], but it would have taken a lot longer to get there ... 1930s as Conner Prairie Farms, after Eli Lilly—grandson of Col.

The shaving giant is looking for around 250,000 square feet of office space as it prepares to move out of, and then perhaps ...

The CityWay development opened in 2013 and transformed what was once a parking lot near Eli Lilly and Co. into a bustling neighborhood in a key area of downtown. The first phase included luxury ...

Indiana's workforce is feeling pressure to return to the office, but a good portion of employees still like hybrid work. Is ...

“It would take a really significant lifestyle change to go back downtown, to buy a new work wardrobe, to pay for parking and driving ... pharmaceutical giant Eli Lilly and Co., who led the ...

Eli Lilly’s momentum stems from blockbuster GLP-1 therapies (Mounjaro, Zepbound), fuelling revenue growth, long-term margin expansion, and an ethos driving America’s health focus across ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli Lilly LLY we detected 116 trades. If we consider the specifics of each ...

Ore Huiying / Bloomberg / Getty Images Pharmaceutical company Eli Lilly is expected to report fourth-quarter earnings before the bell Thursday. Analysts tracking the company see increased sales ...

Getty Images Pharmaceutical company Eli Lilly is expected to report fourth-quarter earnings before the bell Thursday. Analysts tracking the company see increased sales and profit for Eli Lilly in ...

Eli Lilly (NYSE:LLY) is setting the stage for a strong 2025, with its fourth-quarter results and forward guidance reflecting solid momentum. The company's adjusted earnings per share are expected ...

Eli Lilly exceeded analyst forecasts for both sales and earnings in Q4 2024. As has been true for a while, sales of GLP-1 drugs Mounjaro and Zepbound drove both sales and earnings growth.